ArticleMolecular oncology2015
Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Article in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy.Anti-cancer agents in medicinal chemistry · 2025Pooled it
- CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.Journal for immunotherapy of cancer · 2025Article
- Structure-based humanization of a therapeutic antibody for multiple myeloma.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1.Antibodies (Basel, Switzerland) · 2024Article
- Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.Signal transduction and targeted therapy · 2023Article
- Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.Nature medicine · 2023Article
- EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages.Molecular therapy. Methods & clinical development · 2022Article
- Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.International journal of molecular sciences · 2022Article
- Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.Cancer immunology research · 2021Article
- The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.Frontiers in immunology · 2021Review
- Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.Nature communications · 2020Article
- An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery.Molecular therapy. Nucleic acids · 2019Article
- Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Article
- Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?Journal of oncology · 2019Review
- CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.Antibody therapeutics · 2018Article
- Monoclonal antibody therapy in multiple myeloma.Leukemia · 2017Review
- A complex water network contributes to high-affinity binding in an antibody-antigen interface.Data in brief · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is an aggressive incurable plasma cell malignancy with a median life expectancy of less than seven years. Antibody-based therapies have demonstrated substantial clinical benefit for patients with hematological malignancies, particular in B cell Non-Hodgkin's lymphoma. The lack of immunotherapies specifically targeting MM cells led us to develop a human-mouse chimeric antibody directed against the B cell maturation antigen (BCMA), which is almost exclusively expressed on plasma cells and multiple myeloma cells. The high affinity antibody blocks the binding of the native ligands APRIL and BAFF to BCMA. This finding is rationalized by the high resolution crystal structure of the Fab fragment in complex with the extracellular domain of BCMA. Most importantly, the antibody effectively depletes MM cells in vitro and in vivo and substantially prolongs tumor-free survival under therapeutic conditions in a xenograft mouse model. A BCMA-antibody-based therapy is therefore a promising option for the effective treatment of multiple myeloma and autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.